Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.43 |
| ▸ | JAK3 | P52333 | 11/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448469 | 1.00 | BTK (0.43) | BTKJAK3PARP1PIM1PIM2 | |
| SCHEMBL29448493 | 0.91 | PIM1 (0.44) | BTKJAK3PARP1PIM1PIM2 | |
| SCHEMBL22496848 | 0.91 | PIM1 (0.44) | BTKJAK3PARP1PIM1PIM2 | |
| SCHEMBL22497111 | 0.89 | BTK (0.54) | BTKJAK3PARP1PIM1PIM2 | |
| SCHEMBL22497009 | 0.89 | BTK (0.54) | BTKJAK3PARP1PIM1PIM2 | |
| SCHEMBL28606309 | 0.85 | BTK (0.43) | BTKJAK3 | |
| SCHEMBL28606310 | 0.85 | BTK (0.43) | BTKJAK3 | |
| SCHEMBL22497106 | 0.84 | BTK (0.54) | BTKJAK3 | |
| SCHEMBL22496749 | 0.84 | BTK (0.54) | BTKJAK3 | |
| SCHEMBL29448477 | 0.84 | BTK (0.54) | BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | MAP3K5, MAP3K2, MAPKAPK5 | BTK 280/4885JAK3 135/4885PARP1 1177/4885 |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | BTK 280/4885JAK3 135/4885PARP1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.